TO THE EDITOR Chronic plaque psoriasis is a common, genetic, immune-mediated skin disorder that can be dichotomized according to age of onset: early-onset psoriasis (EOP; type 1, onset before 40 years of age, B75% of subjects) and late-onset psoriasis (LOP; type 2, onset over 40 years of age, B25% of subjects; Henseler and Christophers, 1985) .
Recently, genome-wide association studies (GWAS) have made significant strides in elucidating the genetic basis of EOP with a total of 36 loci now identified (Hébert et al., 2012; Tsoi et al., 2012) . In comparison, there are only two genetic studies specifically in LOP: one found no association with HLA-Cw6, the major genetic locus associated with EOP (Allen et al., 2004; Gudjonsson et al., 2006) while a second separate study found a nominal association with a variant (rs16944) mapping to the IL1B promoter region (Reich et al., 2002) .
Inflammatory cytokines, such as IL-1beta (IL1b) and tumor necrosis factoralpha (TNF-a), have a well-documented role in the pathogenesis of psoriasis (Griffiths and Barker, 2007; Nestle et al., 2009) . They are important stimuli of the migration of epidermal Langerhans cells (LC) and plasmacytoid dendritic cells from the skin to draining lymph nodes where they engage with T cells. It has been shown that LC migration in response to these cytokines differs between EOP and LOP (Cumberbatch et al., 2006; Shaw et al., 2010) . This combination of genetic and immunological observations implicating a role for IL1b in mechanisms underlying LOP led us to investigate whether genetic variation at the IL1B gene is associated with psoriasis. We compared association of polymorphisms from IL1B between cohorts of EOP and LOP patients.
Patients of Caucasian descent with chronic plaque psoriasis were recruited from UK Dermatology Centres at Salford Royal NHS Foundation Trust, Manchester, UK; Guy's Hospital, London and the National Hospital for Rheumatic Diseases, Bath, UK. The study adheres to the Declaration of Helsinki Principles, was approved by the relevant local research ethics committees, and all subjects provided written informed consent.
Patients were divided into two subtypes for analysis: EOP (onset o40 years of age) and LOP (onset X40 years). A secondary analysis was conducted, omitting samples with onset between 30 and 50 years of age.
Psoriasis samples were genotyped using the Sequenom MassArray platform with iPLEX Gold chemistry (Sequenom, San Diego, CA) and Taqman (Applied Biosystems, Foster City CA) (rs16944) according to the manufacturer's instructions. Genotypes for control samples were imputed from GWAS data obtained from the Wellcome Trust Case Control Consortium (www.wtccc.org. uk; Wellcome Trust Case Control Consortium, 2007) using IMPUTE v2 (Howie et al., 2009) .
Samples and markers were subjected to quality control and association analysis (Cochran-Armitage test for trend with Fisher's exact test) using PLINK (v1.07) (Purcell et al., 2007) . Any sample or marker with a call rate o90%, a minor allele frequency o5%, or Hardy-Weinberg P-value o1 Â 10 À 4 were removed. Finally, a Bonferroni correction for multiple testing was applied giving a significance threshold of Po3.12 Â 10 À 3 , except for rs16944, which was considered significant at Po0.05 because of prior evidence for association.
A total of 1,906 psoriasis patients were recruited to the study; 1,263 were EOP patients (mean age of onset 20.3 years, SD 9.7 years) and 643 were LOP patients (mean age of onset 50.7 years, SD 9.2 years). Following quality control, data for 16 tagging single-nucleotide polymorphisms (SNPs) were available within the IL1B gene region.
The previously published association at rs16944 (Reich et al., 2002) was replicated in this study (P ¼ 0.03, odds ratio (OR) ¼ 1.15, 95% confidence interval (CI) ¼ 1.02-1.31). Furthermore, rs11687624 (P ¼ 1.53 Â 10 À 3 , OR¼ 1.22, 95% CI ¼ 1.08-1.37), was found to be associated with LOP at Bonferroni significance (Table 1) . SNP rs11687624 is located in the intergenic region between IL1B and IL1A. Another two SNPs, rs1143643 and rs2853550, showed nominal association. When the analysis was performed on those with age of psoriasis onset over 50 years rs2853550 (P X50 ¼ 2.91 Â 10 À 3 , OR¼ 1.53, 95% CI ¼ 1.17-2.01) became significantly associated with LOP. Marker rs11687624, although losing Bonferroni significance, retained a nominal association that was very close to the threshold. SNP rs16944 (P X50 ¼ 3.85 Â 10 À 3 , OR ¼ 1.30, 95% CI ¼ 1.09-1.54) remained significant at Po0.05.
None of the SNPs analyzed in the study were significantly associated with EOP (Table 2) . One SNP, rs12469600 (P ¼ 0.03, OR ¼ 0.89, 95% CI ¼ 0.80-0.99) showed nominal association, however, this was eliminated when samples with psoriasis onset over 30 years were removed.
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It should be noted that the associations reported in this study have not been identified in previous GWAS because of the predominant, if not exclusive use of EOP samples thereby diluting any associations with LOP.
A drawback of the study is the uncertainty that exists surrounding the dichotomy of samples into EOP and LOP. A ''gray area'' exists with disease onset between 30 and 50 years of age where diagnosis is uncertain which has implications for the study in terms of possible false positives. However, we have attempted to counteract this by undertaking a separate analysis removing samples with psoriasis onset between 30 and 50 years. In LOP, the strength of association increased for two SNPs, rs16944 and rs2853550, which reached the Bonferroni threshold for claims of significance despite the reduced sample size. These findings support the association of IL1B with LOP but not EOP.
In conclusion, this is the largest genetic study of LOP to date and has identified IL1B as being significantly and exclusively associated. These results require replication and consideration should be given to the possibility that the disease-causing mutations may not reside within IL1B. Therefore, future work should focus first on fine mapping to find the causative mutations and second on carrying out functional work to establish how the polymorphisms contribute to disease onset at a biological level. Further studies are needed to uncover fully the genetics underpinning LOP and the extent to which they are separable from EOP.
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